| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE45313 | SANOFI-AVENTIS US | Exendin variant peptides |
Jul, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9827379 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
| US9775954 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(2 months ago) | |
| US8603044 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(2 months ago) | |
| US9610409 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
| US9604008 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
| US9408979 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(2 months ago) | |
| US9233211 | SANOFI-AVENTIS US | Relating to a pen-type injector |
Mar, 2024
(2 months ago) | |
| US9526844 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(2 months ago) | |
| US8556864 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
| US9011391 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(a month ago) | |
| US8992486 | SANOFI-AVENTIS US | Pen-type injector |
Jun, 2024
(28 days from now) | |
| US9604009 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9533105 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9623189 | SANOFI-AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9561331 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US8512297 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2024
(4 months from now) | |
| US8679069 | SANOFI-AVENTIS US | Pen-type injector |
Apr, 2025
(11 months from now) | |
| US7918833 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2027
(3 years from now) | |
| US9526764 | SANOFI-AVENTIS US | Combination of an insulin and a GLP-1-agonist |
Oct, 2029
(5 years from now) | |
| US10117909 | SANOFI-AVENTIS US | Combination of an insulin and a GLP-1 agonist |
Oct, 2029
(5 years from now) | |
| US9707176 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(6 years from now) | |
| US10029011 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
Nov, 2030
(6 years from now) | |
| US9821032 | SANOFI-AVENTIS US | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
May, 2032
(8 years from now) | |
| US9717852 | SANOFI-AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
| US9950039 | SANOFI-AVENTIS US | Insulin glargine/lixisenatide fixed ratio formulation |
Dec, 2035
(11 years from now) | |
Soliqua 100/33 is owned by Sanofi-Aventis Us.
Soliqua 100/33 contains Insulin Glargine; Lixisenatide.
Soliqua 100/33 has a total of 26 drug patents out of which 11 drug patents have expired.
Expired drug patents of Soliqua 100/33 are:
- US9827379
- US9775954
- US8603044
- US9610409
- US9604008
- US9408979
- US9233211
- US9526844
- US8556864
- US9011391
- USRE45313
Soliqua 100/33 was authorised for market use on 21 November, 2016.
Soliqua 100/33 is available in solution;subcutaneous dosage forms.
Soliqua 100/33 can be used as improvement in glycemic control in adults with type 2 diabetes mellitus by use of a pen injector with a threaded drive sleeve, improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve, improvement of glycemic control in type 2 diabetes mellitus patients, improvement in glycemic control in adults with type 2 diabetes mellitus inadequately controlled by lixisenatide in combination with metformin and a second oral antidiabetic drug.
Drug patent challenges can be filed against Soliqua 100/33 from 27 July, 2020.
The generics of Soliqua 100/33 are possible to be released after 10 December, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glycemic control in adults with type 2 diabetes mellitus by use of a...
Dosage: SOLUTION;SUBCUTANEOUS
SOLIQUA 100/33 family patents
